ArticleThe Kaohsiung journal of medical sciences2026
Efficacy of CPAP Therapy on Liver Steatosis and Insulin Resistance in Fatty Liver Patients With Obstructive Sleep Apnea: A 4-Year Follow-Up Cohort Study.
Article in The Kaohsiung journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) and obstructive sleep apnea (OSA) are comorbid conditions that synergistically increase cardiovascular risk through systemic inflammation and insulin resistance. While continuous positive airway pressure (CPAP) is the standard treatment for OSA, its efficacy in improving hepatic steatosis and insulin resistance in patients with concurrent MASLD remains unclear. This study aims to characterize metabolic profiles in patients with MASLD stratified by OSA severity and evaluate the longitudinal effects of CPAP therapy on hepatic steatosis and insulin resistance. This retrospective cohort study screened 2429 adults and analyzed 321 patients with computed tomography-confirmed MASLD who underwent polysomnography (PSG) at a tertiary center. Participants were stratified by OSA severity by using the apnea-hypopnea index (AHI). The 4-year longitudinal trajectories of hepatic steatosis were evaluated by employing the hepatic steatosis index (HSI) and those of insulin resistance were investigated by using the triglyceride-to-high-density lipoprotein cholesterol (TG:HDL) ratio and triglyceride-glucose (TyG) index. Moreover, the effects of CPAP therapy on these metabolic indicators were assessed. Compared with other participants, those with severe OSA (AHI ≥ 30) exhibited a significantly higher prevalence of elevated HSI at baseline (p < 0.001) and consistently higher longitudinal levels of HSI, TG:HDL, and TyG over the four-year follow-up. CPAP therapy significantly attenuated insulin resistance in the severe OSA cohort, as reflected by its reduced prevalence of elevated TyG relative to that of the nonuser cohort (27.4% vs. 31.9%, p = 0.043). Longitudinal assessment further identified that CPAP users maintained significantly lower TyG-body mass indices during the first-second year (135.7 vs. 146.6, p = 0.025) and second-third year (133.6 vs. 146.0, p = 0.036) intervals, indicating a sustained metabolic benefit. In conclusion, severe OSA significantly exacerbates metabolic dysfunction in patients with MASLD, necessitating PSG for accurate diagnosis. Long-term CPAP therapy effectively improves insulin resistance specifically in severe OSA cases. Therefore, routine OSA screening and CPAP intervention based on OSA severity are strategies for improving metabolic prognosis in patients with MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.